San Francisco, 13
November 2018: Global In-Vitro Fertilization (IVF) market is expected to reach USD 27 billion by 2022,
according to a new report by Grand View Research, Inc. The market is driven by
the increasing incidence of infertility owing to, lifestyle changes, expansion
of fertility procedures for treating male infertility such as ICSI, government
initiatives to provide better reimbursement policies, and continuous efforts by
the industry contributors.
Moreover, the
availability of genomic testing enabling the prevention of the transfer of
genetic disease during IVF use is further expected to drive the market demand.
The increase in the number of IVF treatment has led more insurance players to
cover the IVF procedures. This has ultimately led to competitive pricing and
has moderated the treatment costs as IVF has been a successfully practiced
technology. This will most likely drive the market by introducing treatment
standardization and automation.
The behavioral shift in
the society is a major factor contributing to the decreased Total Fertility
Rate (TFR). These factors include an increasing number of women in the labor
force, the increased age of the first birth, a shift from rural to urban
societies, lower marriage rates, postponement of marriage, and greater levels
of education for women.
Obesity is another
factor, which has led to an increase in infertility in the population. This is
due to the fact that the fat deposited on women’s abdomen prevents follicular
stimulation and produces male hormones. In the case of males, the rising fat
decreases testosterone levels causing a problem in sperm production. Doctors
have started recommending weight loss in men prior to fertility treatments
along with proper Body Mass Index (BMI) maintenance. The U.S. Endocrine Society
has established the use of Letrozole to increase the testosterone levels in
obese patients.
Access Research Report
of IVF Market@ www.grandviewresearch.com/industry-analysis/in-vitro-fertilization-market
Further
key findings from the report suggest:
· Intracytoplasmic Sperm Injection (ICSI)
dominated the market in 2014.ICSI was introduced in the year 1992 and boosted
the fertility rates from 50% to 80%, according to the American Society for
Reproductive Medicine. In April 2016, Nigeria recorded its first successful
delivery from a frozen egg. Bridge Clinic has stored the eggs using the
flash-freezing technique. With this birth, Nigeria has put itself on the global
map as it now offers IVF through frozen eggs. The eggs were then fertilized
using the ICSI technique.
· Frozen Embryo Replacement (FER) technique
is expected to witness a rapid rise in demand. Conventionally, most embryos
were transferred through fresh cycles. However, with technology refinement, the
number of frozen embryo transfers and the success rates have increased. Moreover,
the policy of freezing the embryos has also reduced the chances of ovarian
hyper-stimulation. The frozen embryo transfers enable single egg transfer,
thus, giving enough time for the endometrial layer to heal from the medicine
stimulation effect. This ensures higher success rates.
· Culture media dominated the overall market
in terms of revenue in 2014. With the increasing government funding and
industrial support for employees for egg/sperm freezing, the demand for
cryopreservation and the needed media for it is expected to witness growth.
There has been an increase in the research activities undertaken to improve the
culture media and to procure maximum boar sperms or eggs, spurring market
growth. Moreover, the increasing number of egg/sperm donor banks is expected to
drive the demand for sperm, egg, and embryo processing media during the
forecast period.
· Europe dominated the IVF market in 2014.
High quality of treatment offered at the most economical price, and the
adherence to medical standards have contributed to its market leadership. In
Europe, the NHS covers three IVF cycles and has also started providing coverage
for gametes freezing. Moreover, the region is an attraction for international
clients as countries, such as Spain, have the highest number of egg donors. The
clinics also provide sex identification and other IVF treatments, which are not
offered in North America.
· North America also accounted for a
significant share of the market in 2014. The standardization of procedures through
automation, regulatory reforms, government funding for egg/sperm storage, and
industry players introducing more IVF treatments are some contributing factors
for North America dominating the IVF market.
· The presence of favorable reimbursement
framework (implementation of USD 50 million 5-year plans by the U.S Department
of Defense for sperm/egg freezing coverage) is also expected to drive regional
market growth over the next six years. The increasing number of clinics
undertaking newer industrial techniques to offer better fertility success rates
is also expected to boost the regional market demand.
· The demand for IVF treatment is expected to
boom in APAC owing to fertility tourism, increasing foreign industries trying
to penetrate the economically developing countries and the changing regulatory
landscape.
· The Asia Pacific Initiative on Reproduction
(ASPIRE), the task force of clinicians and scientists is involved in the
monitoring and management of fertility and Assisted Reproductive Technology
(ART). Such initiatives promote awareness levels thereby, driving growth.
· Industry contributors are introducing newer
automation to shift the IVF treatment from invasive to a minimally invasive or
non-invasive procedure. The industry players are also trying technologies,
which can enable older women to have enhanced fertility rates. For instance, in
August 2015, OvaScience announced the results of its first published analysis
comparing AUGMENT fertility treatment with a standard IVF. The results showed a
significantly higher rate of selection and transfer of embryos as compared to
the standard treatment.
· Some key players in this market includeEMD
Serono Inc., Boston IVF, OvaScience, Thermo Fisher Scientific Inc., Vitrolife
AB, Irvine Scientific, CooperSurgical, Inc., Cook Medical Inc., Genea Biomedx
and Progyny Inc.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/medical-devices
Grand View Research has
segmented the In-Vitro Fertilization (IVF) market on the basis of procedures,
type of cycles, instruments, end-use, and regions:
Global In-Vitro Fertilization (IVF) Procedures Outlook
(Revenue, USD Million, 2012 - 2022)
·
Intracytoplasmic Sperm Injection (ICSI)
·
Frozen Embryo Replacement (FER)
·
Pre-implantation Genetic Diagnosis (PGD)
·
Others
Global In-Vitro Fertilization (IVF) Types of Cycles
Outlook (Revenue, USD Million, 2012 - 2022)
·
Fresh Donor
·
Frozen Donor
·
Fresh Non-donor
·
Frozen Non-donor
Global In-Vitro Fertilization (IVF) Instruments Outlook
(Revenue, USD Million, 2012 - 2022)
·
IVD Disposable Devices
·
Culture Media
·
Capital Equipment
In-Vitro Fertilization (IVF) Regional Outlook (Revenue,
USD Million, 2012 - 2022)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Press Release of
IVF Market@ www.grandviewresearch.com/press-release/global-ivf-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range of
industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment